Protozoa of the genus Trypanosoma cause debilitating disease in humans and animals in Africa. T. brucei rhodesiense, endemic throughout Central and East Africa, is one of the most virulent. It causes n'gana, a fatal wasting disease in domestic animals, and sleeping sickness in humans. The closely related T. brucei gambiense causes West African sleeping sickness, a more slowly progressing disease although also invariably fatal if not treated.
Drugs available for treatment of both of the human African trypanosomiases did not change for over 40 years (27) . Suramin and, more rarely, pentamidine are used during the early nonencephalitic stages of the disease. The arsenical drug melarsoprol (Arsobal) has been the only agent available for late-stage, central nervous system involvement. Chemotherapy is complicated by the need for intravenous administration of suramin and melarsoprol, by a reactive encephalopathy in 1 to 5% of melarsoprol-treated cases, and by the inability of suramin or pentamidine to cure late-stage disease (24, 27) .
Recently an inhibitor of omithine decarboxylase, DLa-difluoromethylornithine (DFMO; eflornithine; Ornidyl) (2) has proven animals. Aside from the few clinical cases noted above, studies of the susceptibility of T. b. rhodesiense to DFMO are limited to three studies with established laboratory strains that indicated that T. b. rhodesiense was less susceptible than T. b. brucei (10, 11, 20) . We therefore examined the susceptibility of a group of T. b. rhodesiense clinical isolates to DFMO and to standard trypanocides. Primary isolates with their inherent mixed populations of parasites were used rather than established and characterized stocks or clones. Despite the variability in results caused by mixed populations, this approach was chosen because the intention was to provide an estimate of the range of drug susceptibilities that will be found in clinical trials and to provide a panel of isolates for evaluation of new therapies before clinical trials. In particular, such results could guide clinical trials planned for DFMO in the near future (19a) . All but two of the T. b. rhodesiense isolates were from the Kenya Trypanosomiasis Research Institute (KETRI) strain bank. They were chosen to obtain a representative geographic distribution in East Africa with emphasis on major endemic areas in Uganda (16). Muguga, Kenya, which had evolved from the East African Mice were separated into groups of five including a group of Trypanosomiasis Research Organization (EATRO) strain five inoculated but untreated control animals for each experbank. All stabilates were isolated from human blood or iment. DFMO was administered ad libitum in the drinking (Table 3) . Since suramin did not cross the blood-brain barrier, the almost universal efficacy of suramin in these studies implies that the test strains did not establish infections in the brain or other areas inaccessible to the drug within the 24-h incubation period before treatment (18, 19) . The drug susceptibility patterns in T. b. rhodesiense strains are shown in Table 4 .
DISCUSSION
Key general issues that appear to be involved in the response of any trypanosome isolate to any drug are as follows: (i) the number of prior syringe passages, since repeated passage is often associated with increasing virulence; (ii) prior selection of resistant organisms by exposure to drug in vivo before the original samples were collected; (iii) the variable time different isolates require to establish infection in sites not accessible to the test drugs; (iv) the degree to which an isolate is able to evade the host immune response, since this will affect the usual synergism between a chemotherapeutic agent and the immune system (12, 26) ; and (v) variable innate biochemical resistance to the drug. We attempted to minimize variables i through iv by beginning treatment 24 h postinfection, using outbred Swiss Webster mice throughout, and using inocula no more than two syringe passages removed from the original strain bank isolate. For 9 of 14 KETRI isolates, no more than two passages had occurred since isolation from the patient, and none had undergone more than 21 passages (Table 1) . Thus the passage artifact was minimal. Most of the KETRI isolates were made before drug treatment, eliminating a selection for drug resistance. The efficacy of suramin in treating all infections except KETRI 243 indicated that the parasites did not become established in sites inaccessible to drugs and that there was little variation in immune system cooperation. We were therefore primarily examining the interaction of the test drugs and the parasites relatively independently of host-parasite model system peculiarities.
The size of the individual test groups was necessarily restricted to allow a broader range of strains and drugs to be tested. However, an examination of Tables 2 and 3 shows that the differences in drug susceptibility were (15, 24) and the laboratory (28) . In addition to KETRI 243, three other isolates were resistant to arsenical compounds.
In spite of the virtual 100% success of DFMO in treating T. b. gambiense, the majority of T. b. rhodesiense strains were at least moderately resistant when inoculated into mice and three were highly resistant. This variable susceptibility could be due to several causes, since DFMO treatment, with the ensuing polyamine deprivation, has many biochemical effects on cells. Polyamine deprivation rapidly inhibits parasite DNA, RNA, and protein synthesis while decreasing parasite multiplication in blood and tissues (1, 5) . Blockage of parasite cell division likely blocks antigenic variation, allowing the parasites to be destroyed by the immune system of the host (6, 11) . Trypanosomes have a spermidine-containing redox intermediate, trypanothione, which is unique to kinetoplastids and may cause them to be particularly susceptible to polyamine depletion (13) .
Data on the mechanism of DFMO resistance have begun to be collected. Greater than 50-fold resistance was experimentally induced in cultured procyclic trypanosomes (analogous to vector midgut forms) by serial passage with increasing drug concentrations (4, 21) . In one strain, the induced resistance was attributed to decreased DFMO uptake (21) . In another it was associated with the ability to maintain a normal concentration of trypanothione in the presence of DFMO; wild-type cells exposed to DFMO have a reduced trypanothione concentration, as would be expected if spermidine biosynthesis were blocked by DFMO (4, 13) . This strain had an elevated intracellular ornithine concentration, which would allow ornithine to compete with the inhibitor, an analog of ornithine, for the active site of ornithine decarboxylase. Ornithine decarboxylase would be thus protected, and polyamine biosynthesis therefore would be maintained in the presence of the drug (4).
Rather than analyzing laboratory-induced DFMO resistance in the noninfectious vector form of the parasite, this study focuses on clinically relevant infective trypanosomes of wild-type, uncloned isolates that have had no prior exposure to DFMO. The reason(s) for the observed resistance to DFMO is not yet known, although it may in part reflect naturally occurring variations in polyamine metabolism. It is intriguing that several strains that are resistant to DFMO are also resistant to arsenical drugs, since the trypanothione-arsenical drug complex formation is believed to be responsible for the action of melarsoprol because the complex inhibits an enzyme that is important for the oxidant stress protection mechanism of the trypanosome (12a, 14) . A naturally occurring excess production of spermidine leading to trypanothione over production might compensate for the arsenical drug-induced loss of trypanothione and confer resistance to both arsenical drugs and DFMO. Further studies with these strains will involve examination of the mechanism(s) for DFMO and arsenical drug resistance and the development of new therapies based on rational combinations of clinically active agents.
In summary, knowledge of the range of susceptibility of wild trypanosome populations to trypanocides is important, since resistance has been a constant problem for the treatment of human and animal trypanosomiases (12, 17, (23) (24) (25) 
